Deferoxamine
- Generic Name
- Deferoxamine
- Brand Names
- Desferal
- Drug Type
- Small Molecule
- Chemical Formula
- C25H48N6O8
- CAS Number
- 70-51-9
- Unique Ingredient Identifier
- J06Y7MXW4D
- Background
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
- Indication
Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
- Associated Conditions
- Aluminum overload, Chronic Iron Overload, Chronic aluminum overload, Iron Overload
- Associated Therapies
- -
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Lipomed
- Target Recruit Count
- 95
- Registration Number
- NCT00350662
- Locations
- 🇪🇬
Pediatric Hospital, Cairo University, Cairo, Egypt
🇹🇷EGE University Medical School, Bornova, Izmir, Izmir, Turkey
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2011-12-12
- Lead Sponsor
- Lipomed
- Target Recruit Count
- 24
- Registration Number
- NCT00349453
- Locations
- 🇨🇭
Cantonal Hospital Graubünden, Chur, Graubünden, Switzerland
🇨🇭Cantonal Hospital, Children's Clinic, Aarau, Aargau, Switzerland
🇨🇭University Children's Hospital, Zurich, Switzerland
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
- Conditions
- Interventions
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 20
- Registration Number
- NCT00115349
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital, Boston, Massachusetts, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
- First Posted Date
- 2003-06-04
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 595
- Registration Number
- NCT00061750
- Locations
- 🇺🇸
Stanford Hospital, Stanford, California, United States
🇺🇸Children's Hospital Oakland, Oakland, California, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 1000
- Registration Number
- NCT00000623
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇺🇸Children's Hospital Oakland, Oakland, California, United States
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.